Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

Andréa Toma, Olivier Kosmider, Sylvie Chevret, +39

Leukemia

Hematological MalignancyTransfusion MedicineHematologyPharmacotherapyMedicine +2

High‐dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study

Lionel Mannone, Claude Gardin, M.C. Quarré, +13

British Journal of Haematology

Hematological MalignancyThrombosisHigh‐dose Darbepoetin AlphaBone Marrow FailureProlonged Half-life +13

A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia

M. Khellaf, J.-F. Viallard, M. Hamidou, +17

Haematologica

Positive Impact of Iron Chelation Therapy (CT) on Survival in Regularly Transfused MDS Patients. A Prospective Analysis by the GFM.

Christian Rosé, Sabine Bréchignac, D. Vassilief, +12

Blood

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

Charikleia Kelaïdi, Sophie Park, Rosa Sapena, +17

Leukemia

Hematological MalignancyThrombosisErythropoiesis-stimulating AgentsBone Marrow FailureHematology +7

A randomized phase II trial of azacitidine +/- epoetin-  in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

Sylvain Thépot, Raouf Ben Abdelali, Sylvie Chevret, +21

Haematologica

ImmunohematologyPharmacotherapyLower-risk Myelodysplastic SyndromesAplastic AnemiaMyeloid Neoplasia +21

Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study

Morgane Cheminant, Coralie Derrieux, Aurore Touzart, +17

Haematologica

High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM

Charikleia Kelaïdi, Odile Beyne‐Rauzy, Thorsten Braun, +23

Annals of Hematology

Darbepoetin AlfaHematologyHigh Response RateTranslational ResearchPharmacotherapy +2

Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases

Raphaël Itzykson, Sameh Ayari, D. Vassilief, +19

Leukemia

Hematological MalignancyBone Marrow FailureMixed-phenotype Acute LeukemiaAplastic AnemiaHematology +8

Chronic Lymphocytic Leukemia Associated with Myelodysplastic Syndrome and/or Chronic Myeloid Leukemia: Evidence for Independent Clonal Chromosomal Evolution

Hossein Mossafa, C. R. Fourcade, M. Pulic, +4

Leukemia & lymphoma/Leukemia and lymphoma